{"id":"W2127018518","doi":"10.1016/s1470-2045(15)70128-2","title":"Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":335,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital","funders":"Genentech","keywords":"Medicine; Internal medicine; Tolerability; Brentuximab vedotin; Rituximab; Antibody-drug conjugate; Oncology; Refractory (planetary science); Lymphoma; Phases of clinical research; Adverse effect; Clinical trial; Antibody; Immunology; Monoclonal antibody; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001001391,0.0002672191,0.001112969,0.00008201844,0.0001121095,0.00001410477,0.0002036917,0.000149679,0.00001222547],"category_scores_gemma":[0.0001553971,0.0001389111,0.00006391523,0.0002638344,0.0003780527,0.00006471055,0.0002409243,0.0002121935,0.000007607597],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002738808,"about_ca_system_score_gemma":0.002755618,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001817466,"about_ca_topic_score_gemma":0.001176426,"domain_scores_codex":[0.997921,0.0006177286,0.0004130707,0.0004016983,0.0002463688,0.0004000845],"domain_scores_gemma":[0.9981904,0.0006199568,0.0003199533,0.0006588202,0.0000667744,0.0001440762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0642446,0.02730581,0.7224991,0.000882865,0.00131957,0.002849232,0.02575926,0.0001643749,0.04780817,0.0002036789,0.003711288,0.103252],"study_design_scores_gemma":[0.2168531,0.01137937,0.7484221,0.0002789526,0.0006866841,0.0005267663,0.001762468,0.00267503,0.008842267,0.00006128293,0.008213401,0.0002985932],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938109,0.00187508,0.000002536164,0.001619056,0.0002213874,0.001329831,0.00002562057,0.00002411533,0.001091478],"genre_scores_gemma":[0.9979154,0.00116034,0.00003970938,0.0004450865,0.0001710409,0.00004784182,0.000006502718,0.00002491892,0.0001891499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1526085,"threshold_uncertainty_score":0.7161887,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03697546453452785,"score_gpt":0.3523724593174217,"score_spread":0.3153969947828939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}